MK-677: The Oral GH Booster With 11 Human Trials, a Failed Alzheimer's Study, and an Appetite Problem

The short version

MK-677 (Ibutamoren) is an oral, non-peptide growth hormone secretagogue developed by Merck. It’s not a peptide and not a SARM — though it’s constantly mislabeled as both.
It has 11 published human clinical trials — more than BPC-157, TB-500, Semax, Selank, CJC-1295, and Ipamorelin combined.
The landmark 2-year RCT (n=65) showed: lean mass increased 1.1 kg vs -0.5 kg placebo (p<0.001), GH and IGF-1 restored to youthful levels, no tolerance over 2 years.
Sleep improvement is the best-supported benefit. A controlled study showed a 50% increase in stage IV (deep) sleep and a 20-50% increase in REM sleep.
The appetite increase is not a side effect — it’s the mechanism. MK-677 is a ghrelin mimetic. Ghrelin is the hunger hormone. You will get hungrier. This is inherent to how the drug works.
Insulin resistance is the most serious concern. Multiple trials show fasting glucose and HbA1c increases. In the 2-year study, 16 subjects crossed into prediabetic ranges. A hip fracture trial was terminated early due to a congestive heart failure signal (6.5% vs 1.7% placebo).
Despite 11 human trials, MK-677 was never FDA-approved. Merck walked away. Only 52% of gray-market products contain what they advertise.

The most evidence-backed compound nobody’s approved

Here’s an odd situation.

Most compounds in the peptide and GH-optimization space have thin evidence — a handful of animal studies, maybe a small pilot trial, and a lot of Reddit anecdotes. We’ve spent the last several articles documenting exactly how wide the gap between popularity and evidence usually is.

MK-677 is different. It has 11 published human clinical trials spanning over a decade of research, including a 2-year randomized controlled trial and a 563-patient Alzheimer’s study. The data on GH elevation, body composition, bone turnover, sleep architecture, and metabolic effects is extensive and specific.

And yet no pharmaceutical company has pursued FDA approval. Merck developed it, ran the trials, got the data, and walked away. Understanding why they walked away tells you as much about MK-677 as the trial results do.

What MK-677 actually is (and isn’t)

Let’s clear up the identity confusion first.

MK-677 is not a peptide. It’s a non-peptide spiroindoline sulfonamide. Its molecular formula is C₂₇H₃₆N₄O₅S. You take it as a pill or liquid — no injections.

MK-677 is not a SARM. It doesn’t bind androgen receptors. It doesn’t affect testosterone. It gets lumped in with SARMs because the same vendors sell it in the same product lines. This is marketing convenience, not pharmacology.

MK-677 is a ghrelin receptor agonist. It binds to the GHS-R1a receptor — the same receptor that ghrelin (your body’s hunger hormone) activates. When ghrelin hits this receptor, two things happen: growth hormone gets released, and you get hungry. MK-677 does both. You cannot separate these effects because they come from the same receptor.

The binding affinity is potent: EC₅₀ of 1.3 nM. Oral bioavailability is high. The half-life is approximately 24 hours, meaning once-daily dosing maintains steady-state levels.

The human evidence — all 11 trials

This is what sets MK-677 apart from everything else in the GH peptide space. Let’s go through the data.

The landmark 2-year RCT

Nass et al. (2008) — Annals of Internal Medicine [PMID: 18981485]

This is the gold standard MK-677 study:

Design: 2-year, randomized, double-blind, placebo-controlled
Subjects: 65 healthy older adults (60-81 years)
Dose: 25 mg/day orally
Results:
- Fat-free mass: +1.1 kg in MK-677 group vs -0.5 kg placebo (p<0.001)
- GH secretion: Restored pulsatile GH to levels seen in young adults
- IGF-1: Increased and sustained for the full 2 years — no tolerance
- Fat mass: No significant change (this is important — MK-677 didn’t reduce fat)
- Body weight: Increased slightly in MK-677 group (appetite effect)
Adverse events:
- Fasting glucose: +5 mg/dL average increase
- HbA1c: +0.2% average increase
- 16 subjects crossed into prediabetic glucose ranges
- Increased appetite (expected from mechanism)
- Mild peripheral edema

Two years. No tolerance. Sustained GH/IGF-1 elevation. But also sustained metabolic cost.

GH restoration in elderly

Chapman et al. (1996) — J Clin Endocrinol Metab [PMID: 8954023]

32 healthy elderly subjects
25 mg MK-677 increased mean 24-hour GH by 97%
10 mg increased GH by 57%
IGF-1 restored to levels seen in young adults
Peak GH response: 55.9 mcg/L (vs ~9 mcg/L placebo)

The sleep study

Copinschi et al. (1997) [PMID: 9467534]

This is the data behind the most consistently reported user benefit:

Stage IV (deep) sleep increased by 50%
REM sleep increased by 20-50%
Effects confirmed via polysomnography (objective brain wave measurement, not self-report)

For context, deep sleep is when your body does most of its physical repair and growth hormone release occurs naturally. Enhancing it by 50% is a meaningful physiological change. This finding aligns with the overwhelming user consensus that sleep improvement is MK-677’s most noticeable benefit — often felt within 3-5 days of starting.

Reversing muscle loss from dieting

Murphy et al. (1998) [PMID: 9467534]

Healthy volunteers placed on caloric restriction (diet-induced catabolism)
MK-677 reversed the negative nitrogen balance: shifted from -1.48 g/day to +0.31 g/day
Translation: MK-677 prevented the muscle breakdown that normally accompanies dieting

This is relevant for anyone using MK-677 during a cut — it may protect lean mass even in a caloric deficit.

Bone health (3 studies)

Svensson et al. (1998): In 24 obese males, MK-677 increased bone formation markers by 15-28% and resorption markers by 23-26% — indicating accelerated bone turnover, not just formation.

Murphy et al. (1999): In 187 elderly subjects, osteocalcin (bone formation marker) increased 29.4%.

Murphy et al. (2001): In 292 osteoporotic women, MK-677 combined with alendronate improved femoral neck bone mineral density by +4.2% vs +2.5% with alendronate alone.

The Alzheimer’s failure

Sevigny et al. (2008) — Neurology [PMID: 19015485]

563 patients with mild-to-moderate Alzheimer’s disease
25 mg MK-677 daily for up to 12 months
IGF-1 increased 73% — confirming the drug worked as expected
Zero clinical benefit for Alzheimer’s symptoms on any cognitive or functional measure

This is a critically important study because it demonstrates a principle that applies across all GH-elevating therapies: raising IGF-1 does not automatically produce the clinical outcome you want. The target was engaged. The biology responded. The disease didn’t care.

The biohacking community largely ignores this trial because it doesn’t fit the narrative. We think it’s one of the most important MK-677 studies because it shows exactly where the “GH goes up therefore good things happen” logic breaks down.

The hip fracture trial — terminated early

Adunsky et al. (2011) [PMID: 21071489]

123 patients recovering from hip fracture
MK-677 25 mg daily
Terminated early due to a congestive heart failure signal: 6.5% incidence in MK-677 group vs 1.7% placebo
The CHF events occurred predominantly in patients with pre-existing cardiovascular risk factors

This is the most serious safety signal in MK-677’s clinical history. It was sufficient to halt the trial and likely contributed to Merck’s decision not to pursue the compound further.

Why Merck walked away

MK-677 has more positive clinical data than most compounds that make it to market. So why didn’t Merck pursue FDA approval?

Seven converging factors:

No clean indication. “Growth hormone deficiency” has established treatments (direct GH). “Anti-aging” isn’t an FDA-approvable indication. The bone density data wasn’t strong enough vs existing bisphosphonates. The Alzheimer’s trial failed.
The insulin resistance signal. Consistent across multiple trials, it’s a significant liability for a drug you’d take long-term.
The CHF signal. Even in a small trial, a 4x difference in heart failure rates is hard to ignore.
The appetite increase. An anti-aging drug that makes elderly people hungrier and gain weight is a tough sell to regulators.
Patent expiration. By the time enough indication-specific data could be generated, patent protection would be gone.
Direct GH competition. Recombinant HGH already exists for GH deficiency. Why fight for approval of a second-line agent?
Risk-benefit calculation. The benefits (lean mass +1.1 kg over 2 years) are real but modest. The risks (insulin resistance, potential CHF, appetite/weight gain) are ongoing.

Merck did the math and decided it didn’t add up. The compound works — but not well enough, for any specific condition, with a clean enough safety profile, to justify the $100-200M Phase 3 investment.

The insulin resistance problem — in detail

This deserves its own section because it’s the most clinically significant risk and the one most frequently glossed over in community discussions.

What the trials show:

Fasting glucose increases of 5-10 mg/dL are consistent across studies
HbA1c increases of 0.2-0.3% are typical
In the 2-year study, 16 subjects crossed from normal to prediabetic glucose ranges
Effects are dose-dependent (worse at 25 mg than 10 mg)
Effects appear to plateau rather than progressively worsen
Effects are at least partially reversible on cessation

The mechanism: GH and IGF-1 are counter-regulatory to insulin. They promote glucose production and reduce glucose uptake. This is normal physiology — your body releases GH during fasting partly to maintain blood sugar. Chronically elevating GH amplifies this effect.

Who’s most at risk:

Anyone with pre-existing insulin resistance or metabolic syndrome
Overweight/obese individuals
Family history of type 2 diabetes
Those on high-carbohydrate diets
Individuals already taking medications that affect glucose metabolism

Practical implication: If you use MK-677, monitor fasting glucose and HbA1c. If either starts climbing, reduce the dose or stop.

MK-677 vs the alternatives

	MK-677	CJC-1295/Ipa	Direct HGH	Tesamorelin
Route	Oral (pill/liquid)	SC injection	SC injection	SC injection
Human RCTs	11	0 (combination)	Multiple	Multiple
Lean mass data	+1.1 kg (2-yr RCT)	None	Yes (strong)	Yes (visceral fat)
Sleep data	+50% deep sleep	None	Yes	Limited
FDA approved	No	No	Yes	Yes
Appetite increase	Significant (inherent)	Minimal	Moderate	Minimal
Insulin resistance	Yes (documented)	Likely (GH class)	Yes	Yes
Cortisol/prolactin	May increase	Ipamorelin: no	No	No
Cost	$50-150/mo	$300-800/mo	$500-3,000/mo	High (branded)
Convenience	Highest (oral)	Daily injection	Daily injection	Daily injection
WADA	Banned	Banned	Banned	Banned

The honest trade-off: MK-677 is the cheapest, most convenient, and most evidence-backed option — but it carries the highest metabolic cost (appetite + insulin resistance + potential cortisol/prolactin effects) and the most significant safety signals (CHF, glucose dysregulation).

Quality — most of what’s sold is garbage

A 2017 JAMA study analyzed products sold as SARMs and GH secretagogues online. The findings:

Only 52% contained the advertised compound
39% contained an unapproved drug not listed on the label
25% contained compounds not on the label that had never been studied in humans
9% contained no active compound at all

MK-677 is sold as capsules, liquid solutions, and raw powder by research chemical vendors. It is not a dietary supplement — the FDA has issued warning letters to at least three companies (Umbrella Labs 2021, Elite Supplement 2022, Warrior Labz 2023) for selling it as one.

In March 2026, a product called Agebox iKids — marketed as a children’s growth supplement — was recalled after testing revealed it contained MK-677. Hidden GH secretagogues in children’s supplements. That’s the market you’re buying from.

If you use MK-677, demand third-party certificates of analysis. If a vendor can’t provide one, that tells you everything.

The practical reality

Common dosing (community, not clinically validated):

10 mg/day: Lower GH elevation but significantly fewer side effects. Gaining traction as the “sweet spot”
12.5 mg/day: Common compromise dose
25 mg/day: The dose used in most clinical trials. Full GH response but full appetite/insulin effects

Timing: Before bed is overwhelmingly preferred — you sleep through the worst of the appetite spike, and the GH pulse aligns with your natural nighttime GH release.

Cycling: Community typically recommends 8-12 weeks on, 4 weeks off. Some use 10 mg year-round. The 2-year Nass study showed no tolerance, but the metabolic effects accumulated.

What users consistently report:

Sleep improvement (days 3-5) — the most reliable benefit
Appetite increase (immediate, peaks weeks 1-2, partially subsides by week 4)
Water retention / face bloating (dose-dependent, resolves within days of stopping)
Gradual body composition changes (months, not weeks)
Joint comfort (weeks 4-6, from GH-mediated collagen synthesis)
Tingling/numbness in hands (carpal tunnel-like, dose-dependent)

What happens when you stop: GH and IGF-1 return to baseline. Appetite normalizes. Water retention clears in days. Body composition changes may partially reverse without the elevated GH support.

Safety summary

Use with caution if:

Pre-existing insulin resistance, metabolic syndrome, or diabetes
History of congestive heart failure or cardiovascular disease
On medications that affect glucose metabolism

Monitor:

Fasting glucose and HbA1c (baseline, 4 weeks, then every 3 months)
IGF-1 levels (target upper-normal, not supraphysiological)
Blood pressure
Signs of fluid retention

Do not use if:

Active cancer (elevated IGF-1 may promote tumor growth)
Type 2 diabetes with poor glycemic control
Active CHF
Pregnancy or breastfeeding
Under 18

The bottom line

MK-677 is the rare compound in this space where the evidence actually matches much of the hype. Eleven human trials confirm it reliably elevates GH and IGF-1, improves sleep architecture, increases lean mass modestly, and supports bone health. The 2-year RCT showing no tolerance is genuinely impressive.

But the evidence also clearly shows the costs: insulin resistance, appetite increase, water retention, and a cardiac safety signal that helped kill the drug’s pharmaceutical future. MK-677 works. The question is whether the metabolic trade-offs are worth it for you specifically.

If your primary goal is sleep improvement, the data is strong. If your primary goal is significant muscle gain or fat loss, the data is surprisingly modest (1.1 kg lean mass over 2 years, no fat loss). If you’re pre-diabetic or metabolically compromised, the insulin resistance signal makes this a poor choice.

It’s the most evidence-backed compound in the GH peptide space. It’s also the one with the most clearly documented downsides. Both things are true at the same time.

Sources

Nass R. et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.” Ann Intern Med. 2008;149(9):601-11. PMID: 18981485
Chapman I.M. et al. “Stimulation of the GH-IGF-I axis by daily oral administration of MK-677 in healthy elderly subjects.” J Clin Endocrinol Metab. 1996;81(12):4249-57. PMID: 8954023
Copinschi G. et al. “Effects of a 7-day treatment with MK-677 on 24-hour growth hormone profiles, IGF-I, and ACTH and cortisol.” Neuroendocrinology. 1997. PMID: 9467534
Murphy M.G. et al. “MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.” J Clin Endocrinol Metab. 1998;83(2):320-5. PMID: 9467534
Svensson J. et al. “Two-month treatment with MK-677 increases GH secretion, FFM, and energy expenditure in obese males.” J Clin Endocrinol Metab. 1998;83(2):362-9.
Svensson J. et al. “MK-677 affects markers of bone metabolism in obese young males.” J Bone Miner Res. 1998.
Murphy M.G. et al. “Effect of MK-677 on bone turnover in healthy older adults.” J Bone Miner Res. 1999.
Murphy M.G. et al. “Effect of alendronate and MK-677 on body composition in elderly women.” J Clin Endocrinol Metab. 2001;86(4):1116-25. PMID: 11502808
Sevigny J.J. et al. “Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.” Neurology. 2008;71(21):1702-8. PMID: 19015485
Adunsky A. et al. “MK-0677 (Ibutamoren mesylate) for the treatment of patients recovering from hip fracture.” Arch Gerontol Geriatr. 2011;53(2):183-189. PMID: 21071489
Chapman I.M. et al. “MK-677 stimulates GH release in healthy young and GH-deficient adults.” J Clin Endocrinol Metab. 1997;82(10):3455-63. PMID: 9329386
Raun K. et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822 (comparison context)
Sigalos J.T. & Pastuszak A.W. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sex Med Rev. 2018;6(1):45-53. PMID: 28778697
Van Cauter E. et al. “Reciprocal interactions between the GH axis and sleep.” Growth Horm IGF Res. 2004;14 Suppl A:S10-7. PMID: 15135771
Colao A. et al. “Systemic complications of acromegaly.” Endocr Rev. 2004;25(1):102-152. PMID: 14769829
JAMA 2017 — Analysis of SARMs/GH secretagogue products: 52% contained advertised compound.
FDA Warning Letter — Umbrella Labs, 2021 (MK-677 sold as dietary supplement)
FDA Warning Letter — Elite Supplement, 2022
FDA Warning Letter — Warrior Labz, 2023
Agebox iKids recall, March 2026 — MK-677 found in children’s growth supplement.
WADA Prohibited List — MK-677 classified under S2.2.4 (Growth Hormone Secretagogues).
Bowers C.Y. et al. Early GHS receptor characterization. Endocrinology. 1976-1984.
Lumos Pharma OraGrowtH program — current MK-677 clinical development for pediatric GH deficiency.
Merck development timeline and patent history for MK-0677.